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Ten  years  ago,  the  first  draft  sequence  of  the  human 
genome was released, ushering in the post-genomic era. 
Since then, the costs of sequencing have plummeted and 
many  new  sequencing  technologies  have  been  intro-
duced.  These  conditions  have  allowed  researchers  to 
investi  gate  a  wide  variety  of  genomes  that  may  be 
important in human health and disease, including those 
of cancer cells and of the organisms that live on our skin 
and  in  our  gut.  Others  have  taken  the  opportunity  to 
revisit  lingering  questions  about  the  human  genome 
itself,  including  those  related  to  gene  number,  the 
importance of non-protein coding genes, and the identifi-
cation of functional and selected variants. Investigators 
from  both  academia  and  industry  interested  in  these 
questions  and  others  gathered  at  the  ‘Beyond  the 
Genome’  conference  in  Boston  recently  to  discuss  the 
current state and future trajectory of genomics research. 
The  meeting  was  organized  by  BioMed  Central  and 
Genome Biology to mark 10 years in science publishing.
In their keynote addresses, Steven Salzberg (University 
of Maryland, College Park, USA) reviewed the history of 
publications  estimating  the  human  gene  count,  while 
George  Church  (Harvard  Medical  School,  Cambridge, 
USA)  discussed  how  the  rapidly  shrinking  costs  of 
sequencing have facilitated the realization of the Personal 
Genome  Project  (PGP)  [http://www.personalgenomes.
org], an effort to obtain and interpret genome infor  ma-
tion by collecting medical information and full genome 
sequences  for  100,000  individuals.  This  will  include 
studies of interactions between genes and environmental 
factors  such  as  microbes  and  immune  responses  to 
allergens, viruses and toxins (Genome+Environment=Trait; 
GET). Currently all publicly available genomes from the 
PGP are integrated into GET-evidence [http://evidence.
personalgenomes.org].
Sequencing cancer and complex disease genomes
The identification of genes with driver mutations critical 
in oncogenesis has been a central aim of cancer research, 
as these genes may represent new drug targets for cancer 
therapies. Alison Klein (Johns Hopkins School of Public 
Health,  Baltimore,  USA)  is  investigating  susceptibility 
genes  for  pancreatic  cancer,  a  particularly  deadly  neo-
plasm. The overall 5-year relative survival for this disease 
is less than 5% and most patients die within 6 to 8 months 
of diagnosis. A family history of pancreatic cancer can be 
found in about 10% of patients, while smoking, obesity 
and diabetes are some significant non-genetic risk factors. 
Traditional  linkage  methods  and  genome-wide  asso-
ciation studies (GWAS) have revealed very few suscep-
tibility loci, and the genetic basis of 90% of the familial 
clustering  of  pancreatic  cancer  remains  un  known. 
However, recent cost reductions in sequencing enabled 
Klein  and  her  group  to  identify  PALB2  (partner  and 
localizer  of  BRCA2)  as  a  candidate  pancreatic  cancer 
gene using exomic sequencing in patients with a family 
history of the disease.
The ability to routinely characterize individual tumor 
genomes may lead to the development of chemo  thera-
peutic regimens tailored to individual cancer patients. 
Elaine  Mardis  (Washington  University  School  of 
Medicine, St Louis, USA) described the Cancer Genome 
Initiative,  which  has  produced  data  from  150  cancer 
genomes  during  the  past  year.  She  pointed  out  that 
whole-genome  sequencing  and  the  analysis  of  cancer 
genomes  will  help  in  understanding  the  evolution  of 
cancer.  However,  as  Steven  Jones  (British  Columbia 
Cancer Agency, Vancouver, Canada) discussed, there are 
critical  issues  that  need  to  be  addressed  if  this 
technology  is  going  to  be  routinely  applied.  These 
include  develop  ment  of  software  tools  for  a 
comprehensive analysis of the genome, the assessment 
of the right level of sampling to identify somatic changes 
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© 2010 BioMed Central Ltdas  well  as  the  clarification  over  the  number  of  false 
negatives. Jones and his group investigated the viability 
of high volume parallel sequen  cing to characterize a rare 
adenocarcinoma  of  the  tongue  before  and  after 
treatment  with  drugs  that  target  growth-factor 
receptors. The study identified genes containing somatic 
protein-coding mutations and copy-number alterations 
in  the  tumor,  and  it  also  has  the  potential  to  identify 
genetic changes associated with drug resistance and to 
elucidate their connection to known cancer pathways.
How much of the genome is functional?
The  true  number  of  genes  in  the  human  genome  is  a 
question  that  has  long  engaged  scientists.  Researchers 
have estimated the human gene complement using many 
different  approaches,  including  cross-species  genome 
comparisons,  extrapolations  based  on  the  number  of 
CpG islands or expressed sequence tags in a particular 
genomic  region  and,  ultimately,  detailed  analyses  by 
automated and manual annotation. Nevertheless, 10 years 
after the first draft of the human genome sequence was 
released, this question still cannot be answered precisely, 
despite the advent of new technologies such as massively 
parallel sequencing of RNA (RNA-seq), which are aiding 
the discovery of new genes and alternative transcripts. 
Some  of  these  new  methods,  including  transcriptome 
reconstruction  from  RNA  sequencing  (RNA-seq)  data, 
were  described  by  Chad  Nusbaum  (Broad  Institute, 
Cambridge, USA). Transcriptome reconstruction, how-
ever, is a difficult task currently. RNA-seq reads are short 
(75 bp); therefore, their assembly and alignment to the 
genome are difficult and can lead to ambiguous align-
ments.  Also,  since  this  technology  allows  direct 
sequencing of RNA fragments, it is tricky to know which 
reads  came  from  which  transcripts  to  distinguish  the 
abundance of alternatively spliced variants.
Chris Ponting (University of Oxford, UK) addressed 
the importance of the human gene count. He and his 
group  estimate  that  between  6.5%  and  10%  of  the 
human genome is under functional constraint and that 
the  human  genome  includes  five  to  eight  times  more 
non  coding than coding bases. This ratio is only about 
two  in  Drosophila  melanogaster,  suggesting  that  the 
fraction of functional DNA in a genome may be a better 
predictor of organismal complexity than gene number. 
If this is the case, it calls for additional attention to be 
paid  to  the  functional  classification  of  genes.  Work 
within  the  GENCODE  (Encyclopedia  of  Genes  and 
Gene  Variants)  consortium  aimed  at  producing  a 
human  reference  gene  set  has  already  moved  in  this 
direction  by  annotating  alternative  splice  variants  in 
rich detail and by estimating the functional potential of 
all  transcripts.  The  current  human  gene  count  in  the 
GENCODE  set  is  21,671  protein-coding  genes 
(described  by  Clara  Amid,  Welcome  Trust  Sanger 
Institute, Hinxton, UK); a further 1,451 transcripts have 
been  classified  as  large  intergenic  noncoding  RNAs 
(lincRNAs), while another 8,529 have been annotated as 
processed  transcripts,  which  will  undergo  additional 
sub-classification as the project proceeds.
Evolutionary insights from genomic analysis
There is not just one human genome. The nucleotide 
sequence  varies  from  individual  to  individual,  from 
popu  lation  to  population,  and  from  continent  to 
continent.  Taking  a  quantitative  view,  Stephan 
Schuster  (Pennsylvania  State  University,  University 
Park,  USA)  reported  that  Europeans  tend  to  differ 
from  one  another  by  about  3.3  million  single-
nucleotide  polymorphisms  (SNPs).  However,  he  and 
his colleagues found that this number increases to 4 
million SNPs when comparing two African Bushmen. 
In an effort to fully characterize the genetic diversity 
represented by African hunter-gatherer groups like the 
Bushmen,  Schuster  has  begun  a  project  to  sequence 
several  Bushmen  individuals  and  compare  these 
genomes to one from an African Bantu.
The  genetic  differences  that  distinguish  individual 
Africans  from  each  other  and  from  non-Africans 
include functional variants. Sarah Tishkoff (University 
of  Pennsylvania,  Philadelphia,  USA)  has  studied 
several  African  populations  that  demonstrate  lactase 
persistence and found that the mutations that confer 
this phenotype in Africa are different from those found 
in Europe and the Middle East. She has also described 
a number of nonsynonymous mutations found only in 
Africans  that  interfere  with  the  perception  of  bitter 
taste  through  their  effects  on  TAS2R38,  a  taste-
receptor gene. Polymorphic sites in the human genome 
that have phenotypic effects, like the SNPs in TAS2R38 
and  those  near  the  lactase  gene,  are  of  particular 
interest to researchers. One way to identify functional 
polymorphisms is to look for regions of the genome 
that appear to have been subjected to selection. This 
can be done by analyzing genomic data using various 
tests that detect unusual patterns of allele frequency 
variation  at  a  given  polymorphism  or  of  haplo  type 
structure  surrounding  the  polymorphism.  Shari 
Grossman  (Broad  Institute,  Cambridge,  USA)  has 
developed  a  new  technique  called  the  Composite  of 
Multiple  Signals  (CMS)  method,  which  uses  several 
such  tests  in  concert  to  help  distinguish  selected 
variants from their linked neighbors. She is currently 
working on applying this approach to preliminary data 
from  the  1,000  Genomes  Project  [http://
www.1000genomes.org], which is expected to contain 
more  information  about  rare  variants  in  the  human 
genome than previous SNP datasets.
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Humans  play  host  to  a  huge  number  of  microbes; 
whereas  each  of  us  is  composed  of  about  10  trillion 
human cells, we also have about 100 trillion bacteria - 
the human microbiome - living inside us or on our skin. 
Human  microbial  communities  change  over  time,  and 
vary  between  individuals,  body  sites,  and  different 
pathologic and physiological states. The association of 
the  human  microbiome  with  various  pathologies  has 
recently  become  the  subject  of  intense  interest.  Jun 
Wang  (Beijing  Genomics  Institute,  Shenzhen,  China) 
described work showing that gut bacterial communities 
are  strikingly  different  in  individuals  with  ulcerative 
colitis  or  Crohn’s  disease  relative  to  healthy  controls. 
Julie Segre (National Human Genome Research Institute, 
National Institutes of Health, Bethesda, USA) reported 
similar findings for the skin microbiome in patients with 
eczema  and  other  skin  disorders.  Segre’s  lab  is  also 
exploring whether these microbes play a causative role 
in disease traits, investigating the effects of skin bacteria 
on wound healing in diabetic mice. Recent work by Rob 
Knight  (University  of  Colorado,  Boulder,  USA)  has 
showed  that  microbes  can  influence  the  phenotype  of 
their host. His group found that the gut flora of leptin-
mutant  mice  is  substantially  different  from  that  of 
normal  mice  and  that  the  transfer  of  bacteria  from 
mutant mice to control mice can result in weight gain. 
Working in conjunction with George Church, Knight is 
involved in an effort to characterize and document the 
microbiomes  of  the  Personal  Genome  Project 
volunteers. Jennifer Wortman (University of Maryland 
School  of  Medicine,  Baltimore,  USA)  spoke  about  an 
initiative  by  the  Human  Microbiome  Project  to  make 
human  microbiome  data  like  this  publicly  available 
through its web portal [http://www.hmpdacc.org].
Current genomics research is focused on both newly 
formulated  inquires  and  longstanding  questions  about 
the composition, content and functionality of the human 
genome  and  the  genomes  of  other  organisms.  The 
constant introduction of new technological innovations 
for  collecting  genomic  information  ensures  that 
genomics  research  will  continually  be  aided  by  new 
investigative  techniques  and  driven  by  ever-increasing 
amounts of data. The future of this research is likely to 
include  translational  work  leading  to  the  further 
development  of  personalized  and  genetic  medicine.  At 
the  same  time,  dramatic  increases  in  the  number  of 
genomic sequences available for analysis are likely to add 
to our understanding of how genomes change over time 
and how they are used as the blueprints for organisms.
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